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THE PATENTABILITY OF THE CRISPR-CAS9 GENOME EDITING
TOOL
DEBORAH KU
ABSTRACT
The biotechnology sector is rapidly changing with the increase in
technological advancements. 1 The laws governing patent protection,
specifically the laws governing patent eligibility, have also changed to adapt
to these innovations.2 This paper focuses on the CRISPR-Cas9 technology,
a genome editing tool that is changing the field of genetic engineering.3 As
of November 2016, the U.S. Patent and Trademark Office has issued 42
patents on the CRISPR-Cas9 technology.4 This paper addresses the issue of
whether patents claiming the core CRISPR-Cas9 technology can survive a
35 U.S.C. §101 (“§101”) subject matter eligibility challenge. The paper
concludes that the CRISPR-Cas9 technology is patentable subject matter
under §101. In reaching this conclusion, the paper will do the following:
explain the CRISPR-Cas9 technology, compare it to genome editing tools
that utilize ZFNs and TALENs, examine relevant §101 Supreme Court and
Federal Circuit decisions, introduce the current Alice framework, and apply
it to a hypothetical §101 invalidity dispute.

1. Timeline of Medical Biology, AMGEN, http://www.biotechnology.amgen.com/timeline.html
(last visited Jan. 20, 2017).
2. Arti K. Rai & Jacob S. Sherkow, The Changing Life Science Patent Landscape, 34 NATURE
BIOTECH. 292, 292-94 (2016).
3. Ekaterina Pak, CRISPR: A Game-changing Genetic Engineering Technique, SITN BLOG (July
31, 2014), http://sitn.hms.harvard.edu/flash/2014/crispr-a-game-changing-genetic-engineeringtechnique.
4. Lee McGuire, For Journalists: Statements and Background on the CRISPR Patent
Interference Process, BROAD INSTITUTE (Dec. 6, 2016),
https://www.broadinstitute.org/crispr/journalists-statement-and-background-crispr-patent-interfer.
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I. CRISPR TECHNOLOGY: A PRECISE GENOME EDITING TOOL
CRISPR, a genome editing technology, has been hailed as “the biggest
biotech discovery of the century.” 5 CRISPR is not the first or the only
genome editing tool available to researchers.6 However, it has generated a
substantial amount of excitement and concern among not only scientists, but
those outside of the scientific community as well.7 CRISPR has been used in
mice to treat sickle cell anemia, a debilitating blood disorder caused by a

5. Antonio Regalado, Who Owns the Biggest Biotech Discovery of the Century?, MIT TECH.
REV. (Dec. 4, 2014), https://www.technologyreview.com/s/532796/who-owns-the-biggest-biotechdiscovery-of-the-century.
6. See Gene Editing, HORIZON, https://www.horizondiscovery.com/gene-editing (last visited Jan.
20, 2017); Hyongbum Kim & Jin-Soo Kim, A Guide to Genome Engineering with Programmable
Nucleases, 15 NAT. REV. GENET. 321 (2014).
7. See Bruce Booth, Riding the Gene Editing Wave: Reflections on CRISPR/Cas9’s Impressive
Trajectory, FORBES (May 31, 2016), http://www.forbes.com/sites/brucebooth/2016/05/31/riding-thegene-editing-wave-reflections-on-crisprs-impressive-trajectory/#184c8697141c.
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single nucleotide change (i.e. A to T) in the DNA. 8 CRISPR screening
technologies have also been implemented to identify human host proteins
that are vital to Zika and dengue viral replication.9 Even more, CRISPR was
used on a human for the first time this year.10 Chinese scientists are currently
conducting human trials with CRISPR on patients suffering from a specific
form of lung cancer. 11 This genome editing tool is reshaping the way
scientists conduct research, and is predicted to revolutionize not only the
fields of medicine, biology, and agriculture, but much like cars, the way
humans live.12
A. The CRISPR-Cas9 System: A Closer Look
CRISPR stands for Clustered Regularly Interspaced Short Palindromic
Repeats, and is used to refer to the entire CRISPR/CRISPR-associated (Cas)
system.13 The CRISPR-Cas9 system (hereinafter “CRISPR”), as previously
mentioned, is a genome editing tool.14 In order to understand how CRISPR
can be used to manipulate genes, it is necessary to understand the general
overview of the central dogma of molecular biology.15 Each gene provides
instructions for building a particular protein.16 This information is stored in
the DNA. 17 Characteristics such as eye color, hair color, and physical
features are all manifested through the proteins our bodies make. 18
Therefore, a cell makes a particular protein from the information stored in
8. See generally Heidi Ledford, CRISPR Deployed to Combat Sickle-cell Anaemia, NATURE
(Oct. 12, 2016), http://www.nature.com/news/crispr-deployed-to-combat-sickle-cell-anaemia-1.20782.
9. Jim Fessenden, Scientists Use CRISPR to Discover Zika and Dengue Weaknesses, PHYS.ORG
(June 21, 2016), https://phys.org/news/2016-06-scientists-crispr-zika-dengue-weaknesses.html.
10. Timothy J. Seppala, China Completes First Human Trial with CRISPR-edited Genes,
ENGADGET (Nov. 15, 2016), https://www.engadget.com/2016/11/15/china-completes-first-human-trialwith-crispr-edited-genes/.
11. PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer,
CLINICALTRIALS.GOV (Nov. 2016), https://clinicaltrials.gov/ct2/show/NCT02793856.
12. See Maywa Montenegro, CRISPR is Coming to Agriculture- with Big Implications for Food,
Farmers, Consumers and Nature, ENSIA (Jan. 28, 2016), https://ensia.com/voices/crispr-is-coming-toagriculture-with-big-implications-for-food-farmers-consumers-and-nature/.
13. Martin Jinek et al., A Programmable Dual-RNA-guided DNA Endonuclease in Adaptive
Bacterial Immunity, 337 SCI. 816 (2012).
14. Regalado, supra note 5.
15. See Central Dogma (DNA to RNA to Protein), KHANACADEMY,
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/ (last visited Dec. 23,
2016).
16. See Intro to Gene Expression (Central Dogma), KHANACADEMY,
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/central-dogmatranscription/a/intro-to-gene-expression-central-dogma (last visited Dec. 23, 2016).
17. Id.
18. Id.
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our DNA through a process known as gene expression.19 The cell will find
the appropriate gene and create a copy of the gene (i.e. the instruction set)
through a process known as transcription.20 This copy is called messenger
RNA (mRNA). mRNA is then read and “decoded” to build a protein through
a process called translation.21
CRISPR, in the simplest terms, can be described as an RNA-guided
nuclease system. RNA, a chemical cousin of DNA, can recognize and bind
to a matching DNA sequence.22 A nuclease is a type of enzyme that can cut
DNA. 23 Therefore, CRISPR is a 2-part system that consists of a Cas9
nuclease, which acts as a pair of “molecular scissors,”24 and a guide RNA
(gRNA), which leads the Cas9 nuclease to the target DNA sequence.25 The
gRNA, which consists of roughly 20 nucleotides (bases), can be
programmed to match with specific sequences in the DNA.26 Researchers
studying a specific genetic disorder can design a gRNA27 or simply order it
online.28
Once in the cell, the gRNA and Cas9 bind together to form a Cas9gRNA complex. 29 This Cas9-gRNA complex then searches through the
entire genome to find the exact portion of the DNA that matches with the 20

19.
20.
21.
22.

Id.
Id.
Id.
Jekaterina Aleksejeva, RNA Facts—the Ultimate Guide to the Chemical Cousin of DNA,
LEXOGEN (July 6, 2016), https://www.lexogen.com/rna-facts-the-ultimate-guide-to-the-chemicalcousin-of-dna/.
23. CRISPR Systems in Prokaryotic Immunity, DOUDNA LAB (2012),
http://rna.berkeley.edu/crispr.html (last visited Jan. 26, 2017); s). ee also Why is Everyone Talking
About CRISPR-Cas9 Technology?, DNA-SCISSORS (June 6, 2016), https://dnascissors.wordpress.com;
Peter Cavanagh & Anthony Garrity, The Answer, CRISPR/CAS9 BLOG,
https://sites.tufts.edu/crispr/answer/ (last visited Jan. 26, 2017).
24. Guy Riddihough, CRISPR Cas9 Molecular Scissors, 351 SCI. 827, 827 (2016),
http://science.sciencemag.org/content/351/6275/827.1; Ellen Jorgensen, What You Need to Know About
CRISPR, TEDSUMMIT (Oct. 24, 2016),
https://www.ted.com/talks/ellen_jorgensen_what_you_need_to_know_about_crispr.
25. Id. See also Cavanagh & Garrity, supra note 23.
26. Jorgensen, supra note 24; CRISPR Systems in Prokaryotic Immunity, supra note 23.
27. Kenian Chen et al., CRISPR Explorer: A Fast and Intuitive Tool for Designing Guide RNA for
Genome Editing, 3 J. BIOLOGICAL METHODS e56 (2016).
28. John Doench, How to Design Your gRNA for CRISPR Genome Editing, ADDGENE (Feb. 16,
2016), https://innovativegenomics.org/blog/how-to-make-a-guide-rna-for-cas9/. See Jacob Corn, How
to Make a Guide RNA for a Cas9 Knockout, INNOVATIVE GENOMICS INITIATIVE (Aug. 12, 2014),
https://innovativegenomics.org/blog/how-to-make-a-guide-rna-for-cas9/.
29. Jeffry D. Sander & J. Keith Joung, CRISPR-Cas Systems for Editing, Regulating, and
Targeting Genomes, 32 NATURE BIOTECH. 347, 349 fig.2b (2014).
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nucleotides of the gRNA.30 When CRISPR finds this region, the gRNA will
insert itself between the two strands of the DNA and latch onto the
corresponding DNA sequence.31 This will trigger the Cas9 enzyme to cut the
DNA, introducing a double stranded break (DSB).32 This break is important
because DNA needs to be stable. 33 At this point, one of two main repair
pathways can be used to fix the break.34 The cell can repair the DSB on its
own through a process known as “non-homologous end joining” (NHEJ), or
through a process known as homologous recombination (HR).35
With NHEJ, the broken ends of the DNA are rapidly joined together.36
NHEJ, however, is an error-prone repair process that results in the insertion
or deletion of one or more bases at the site of repair.37 Adding or removing
a base (i.e. nucleotide) results in a frameshift mutation because it causes a
shift in the codon reading frame.38 Codons, each consisting of 3 nucleotides,
code for amino acids.39 Amino Acids are the building blocks of proteins.40
Frameshift mutations can introduce premature stop codons and result in
many amino acid changes that prevent the protein from properly

30. Id.; CRISPR/Cas9 Guide, ADDGENE, https://www.addgene.org/crispr/guide (last visited Jan.
28, 2017); Jennifer Doudna, Genome Engineering with CRISPR-Cas9: Birth of a Breakthrough
Technology, IBIOLOGY (Mar. 23, 2015), https://www.ibiology.org/ibiomagazine/jennifer-doudnagenome-engineering-with-crispr-cas9-birth-of-a-breakthrough-technology.html. See also Jorgensen,
supra note 24.
31. Sander & Joung, supra note 29, at 349 fig.2b; CRISPR/Cas9 Guide, supra note 30; Doudna,
supra note 30. See also Jorgensen, supra note 24.
32. Sander & Joung, supra note 29 at 351, fig.4.
33. Doudna, supra note 30; Jorgensen, supra note 24; see also A. J. Davis & D. J. Chen, DNA
Double Strand Break Repair Via Non-homologous End-joining, 2 TRANS. CANCER RES. 130, 132
(2013).
34. D. Akcay et al., The Past, Present and Future of Gene Correction Therapy, 3 ACTA MEDICA
51, 54-55 (2014).
35. Id.
36. Id. at 55.
37. Id. at 54-55.
38. Id.
39. Central Dogma and the Genetic Code, KHANACADEMY,
https://www.khanacademy.org/science/biology/gene-expression-central-dogma/central-dogmatranscription/a/the-genetic-code-discovery-and-properties (last visited Jan. 27, 2017).
40. Id.
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functioning.41 Hence, the NHEJ process can be used to inactivate a gene (i.e.
“knock out” a gene).42
DSBs can also be repaired through the HR process if an identical
sequence homology is present in the cell.43 Unlike NHEJ, HR repairs the
DSB by using an undamaged identical DNA template.44 Researchers can use
an artificial DNA sequence to trigger HR, and “knock in” or even “knock
out” genes at target locations.45 This process introduces three components
into the cell: the gRNA, Cas9, and a piece of DNA (donor DNA).46 When
the Cas9 enzyme makes a DSB in the DNA, the cell will look for a related
DNA sequence to use as a template to repair the DNA.47 Humans inherit two
sets of chromosomes from each parent. 48 When a DSB occurs in diploid
organisms such as humans, the sister chromatid is usually used as a template
in the HR process to repair the DNA.49 However, researchers can trick the
cell into using a foreign donor DNA to mend the break. 50 In this case, the
donor DNA is designed such that the specific elements to be added are in the
middle, and the ends consist of arms (homology arms) that are homologous
to the corresponding end regions of the DSB. 51 Hence, when the Cas9

41. What Kinds of Gene Mutations are Possible? G1 10ENETICS HOME REF.,
https://ghr.nlm.nih.gov/primer/mutationsanddisorders/possiblemutations (last visited Feb. 14, 2017); see
also Abby Dernburg, Lecture 4: Classification of Mutations by Their Effects on the DNA Molecule,
http://mcb.berkeley.edu/courses/mcb142/lecture%20topics/Dernburg/Lecture6_Chapter8_screenviewin
g.pdf (last visited Dec. 23, 2016).
42. What Kinds of Gene Mutations are Possible?, supra note 41. See also Dernburg, supra note
41.
43. Akcay, supra note 34, at 54.
44. Id.
45. Ignazio Maggio & Manuel A. F. V. Goncalves, Genome Editing at the Crossroads of
Delivery, Specificity, and Fidelity, 33 TRENDS BIOTECH. 280, 280-81 (2015). See also Akcay, supra
note 34, at 54.
46. Id. at 280; Generating a Knock-out Using CRISPR/Cas9, ADDGENE,
https://www.addgene.org/crispr/guide/#ko-generation (last visited Feb. 14, 2017).
47. Martin Jinek et al., RNA-programmed Genome Editing in Human Cells, 2 eLIFE e00471
(2013), http://dx.doi.org/10.7554/eLife.00471. See also Jorgensen, supra note 24; Jennifer Doudna,
How CRISPR Lets Us Edit Our DNA, TED (Sept. 2015),
https://www.ted.com/talks/jennifer_doudna_we_can_now_edit_our_dna_but_let_s_do_it_wisely.
48. April Klazema, Haploid vs Diploid Cells: How to Know the Difference, UDEMYBLOG (June
13, 2014), https://blog.udemy.com/haploid-vs-diploid.
49. Tamara Goldfarb & Michael Lichten, Frequent and Efficient Use of the Sister Chromatid for
DNA Double-Strand Break Repair during Budding Yeast Meiosis, 8 PLOS BIO. e1000520 (2010),
10.1371/journal.pbio.1000520; see also Jorgensen, supra note 24; Doudna, supra note 30.
50. The Basics of CRISPR/Cas9, GENOME EDITING UIC,
https://sites.google.com/site/genomeedits/basics (last visited Feb 15, 2017); see also Jorgensen, supra
note 24; Doudna, supra note 30.
51. Akcay, supra note 34 at 54fig1; s. ee also Chari Cortez, CRISPR 101: Homology Directed
Repair, ADDGENE BLOG, http://blog.addgene.org/crispr-101-homology-directed-repair (last visited Feb
15, 2017).
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enzyme makes the cut, the cell proceeds to incorporate it into the gap through
HR instead of NHEJ.52
This idea of using donor DNA to introduce desired genes into our cells
opens endless possibilities because HR is considered to be a more accurate
and precise repair pathway than NHEJ. 53 With HR, researchers are
theoretically able to turn on and off genes at targeted locations without
disrupting untargeted parts of the genome.54 There are currently over 10,000
human diseases caused by a mutation in a single gene. 55 Single gene
disorders, also known as monogenic diseases, include Huntington’s disease,
Cystic Fibrosis, Sickle cell anemia, Tay sachs disease, and Thalassaemia.56
Beyond single gene disorders, researchers believe CRISPR will one day be
used to cure complicated genetic disorders, and even prevent disorders such
as Down syndrome before a child is born.57
B. CRISPR, ZFNs, and TALENs
CRISPR is the latest genome editing tool to enter the biotech field, but
it is not the only tool that can make DSBs. 58 The CRISPR system, as
previously mentioned, relies on a programmable RNA-guided nuclease to
target specific DNA sequences.59 Currently, researchers are using the Cas9
enzyme to cleave DNA.60 However, it is only a matter of time before a more
efficient RNA-guided nuclease is discovered. 61 For instance, the Cpf1
enzyme was recently found to be easier to use and produce less errors in
comparison to the Cas9 enzyme.62

52. Id.
53. Cortez, supra note 51.
54. Jelor Gallego, Modified CRISPR Can Now Turn Gene Expression On and Off, FUTURISM
(Mar. 17, 2016), https://futurism.com/modified-crispr-can-now-turn-gene-expression-off.
55. Genes and Human Disease, WORLD HEALTH ORG.,
http://www.who.int/genomics/public/geneticdiseases/en/index2.html (last visited Dec. 23, 2016).
56. Id.
57. CRISPR . . . Changing the World, GENOME COMPILER (Nov. 12, 2013),
http://www.genomecompiler.com/crispr-changing-the-world.
58. Akcay, supra note 34, at 60-61.
59. Jinek, supra note 13, at 816.
60. Id.
61. Mike Williams, Rice Lab Offers New Strategies, Tools for Genome Editing, RICE (Feb. 8,
2016), http://news.rice.edu/2016/02/08/rice-lab-offers-new-strategies-tools-for-genome-editing.
62. Bernd Zetsche et al., Cpfl is a Single RNA-guided Endonuclease of a Class 2 CRISPR-Cas
System, 163 CELL 759 (2015).
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Researchers have been, and are still using other technologies that utilize
programmable nucleases to modify eukaryotic genomes. 63 Technologies
based on artificial enzymes known as zinc finger nucleases (ZFNs) and
transcription activator-like effector nucleases (TALENs) have also been
used by researchers for years.64 Researchers have been using technologies
based on ZFNs and TALENs to study how our genes work in mice, rats, and
in various cell lines similar to those in humans.65 ZFNs, which have been in
use since the mid-1990s, was tested for the first time by U.S. researchers in
2014 on 12 HIV patients.66 ZFN-based technology was used to modify the
gene encoding CCR5, the “Trojan horse” used by HIV to infect the human
immune system.67 Similarly, in 2015, TALEN-based technology was used
for the first time in a human by British researchers.68 It was successfully used
to treat a baby diagnosed with acute lymphoblastic leukemia.69 Technologies
utilizing ZFNs, TALENs, and CRISPR largely make up the genome editing
market today.70 It is currently a $2.84 billion-dollar industry that is projected
to nearly double in revenue by 2021.71
C. Why is CRISPR Special?
The two major repair pathways NHEJ and HR are not new. 72
Researchers have been studying these pathways for years by implementing
them in fruit flies and lab animals.73 Gene editing tools that make DSBs are
not new. 74 Moreover, tools utilizing programmable nucleases to target
specific DNA sequences are not new.75 Technologies based on ZFNs and

63. Akcay, supra note 34, at 60-61.
64. Akcay, supra note 34, at 55-57.
65. Id.
66. Sara Reardon, Gene-editing Method Tackles HIV in First Clinical Test, NATURE (Mar. 5,
2014), http://www.nature.com/news/gene-editing-method-tackles-hiv-in-first-clinical-test-1.14813.
67. Id.
68. Sara Reardon, Leukemia Success Heralds Wave of Gene-editing Therapies, NATURE (Nov.
10, 2014), http://www.nature.com/news/leukaemia-success-heralds-wave-of-gene-editing-therapies1.18737.
69. Id.
70. RnR Market Research, Genome Editing Market (CRISPR, TALEN, ZFN) to See 14.3% CAGR
to 2021, PR NEWSWIRE (Oct. 13, 2016), http://www.prnewswire.com/news-releases/genome-editingmarket-crispr-talen-zfn-to-see-143-cagr-to-2021-596898941.html.
71. Id.
72. Akcay, supra note 34, at 53-55.
73. Id. at 56.
74. Id. at 53.
75. Id. at 60-61.
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TALENs are still being used even with the rise of CRISPR. 76 Further,
genome editing technology has successfully been used in humans to treat
genetic conditions.77 At this point, it is only logical to ask why CRISPR is
considered to be “revolution”78 if it is not doing something new.
First, CRISPR is relatively simpler to use in comparison to the other
options. 79 ZFN and TALEN based technology rely on proteins for DNA
recognition. 80 This means that every time a researcher wants to target a
different segment of the DNA, a new protein needs to be engineered. 81
Unlike ZFNs and TALENs, CRISPR relies on RNA and complementary
base pairing for DNA recognition.82 A researcher using CRISPR need only
synthesize a 20-nucleotide strand of gRNA, which is simple compared to the
amount of work that goes into ZFN and TALEN based technology. 83 ZFN
and TALEN are difficult to engineer, require sophisticated protein
engineering, and involve a certain degree of trial and error (depending on
how complex the sequence is). 84 Today, do-it-yourself (DIY) bacterial
CRISPR kits are available for sale on the market. 85 These DIY kits give
people outside of the scientific community a chance to use CRISPR to
modify genes of a strain of bacteria.86
Second, CRISPR is a much cheaper alternative to ZFNs and TALENs
due to its simplicity.87 ZFN enzymes cost anywhere from $4,000 to $7,000 a
piece.88 TALEN plasmids, on the other hand, cost only $65 a piece, with the

76. Id.
77. Reardon, supra note 68.
78. Jennifer Doudna, Genome-editing Revolution: My Whirlwind Year with CRISPR, NATURE
(Dec. 22, 2015), http://www.nature.com/news/genome-editing-revolution-my-whirlwind-year-withcrispr-1.19063; Brad Plumer & Janvier Zarracina, Guide to CRISPR Gene Editing Revolution, GENETIC
LITERACY PROJECT (Jan. 3, 2017), https://www.geneticliteracyproject.org/2017/01/03/guide-crisprgene-editing-revolution; Bruce Booth, CRISPR/Cas9 Already is a Revolution in Molecular Biology,
MEDCITYNEWS (June 9, 2016), http://medcitynews.com/2016/06/crispr-cas9-revolution.
79. Paul BG van Erp et al., The History and Market Impact of CRISPR RNA-guided nucleases, 12
CURRENT OPINION IN VIROLOGY, 85, 85-90 (2015).
80. Id. at 86.
81. Id.
82. Id.
83. Id.
84. Id.
85. Andrew Tarantola, I Played God with the Odin’s DIY CRISPR Kit, ENGADGET (June 30,
2016), https://www.engadget.com/2016/06/30/i-played-god-with-the-odins-diy-crispr-kit.
86. Id.
87. van Erp et al., supra note 79, at 87.
88. Brian Wang, Disruptive CRISPR Gene Therapy is 150 Times Cheaper Than Zinc Fingers and
CRISPR is Faster and More Precise, NEXT BIG FUTURE (June 9, 2015),
http://www.nextbigfuture.com/2015/06/disruptive-crispr-gene-therapy-is-150.html; see Heidi Ledford,
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popular Golden Gate TALEN Kit priced at $425.89 For research labs across
the world, purchasing just one customized mouse or rat model could cost up
to $20,000.90 CRISPR on the other hand, can cost as little as $30.91 This is
because researchers generally only need to purchase the RNA segment. 92
CRISPR gives more labs the ability to design CRISPR systems on their own
because it does not require complex engineering like ZFNs and TALENs
do.93
Third, CRISPR is much more efficient than ZFNs and TALENs. 94
Efficiency rates for CRISPR in eukaryotic cells was higher than the rates
reported for ZFNs and TALENs. 95 Unlike ZFNs and TALENs, CRISPR
allows researchers to modify several genes at once by introducing multiple
gRNAs. 96 Before CRISPR, it could take anywhere from 6 to 12 or more
months to genetically engineer mice to carry mutations in several genes.97
Today, labs using CRISPR can implement the same process and generate the
same results within one month.98 CRISPR has also changed the way whole
genomes are screened.99 One research lab used CRISPR with nearly 65,000
different gRNAs to target 18,000 genes.100 Because of its efficiency, cost,
and ease of use, CRISPR has changed the way scientific research is
conducted.101 It is predicted that every research lab in the future will be using
CRISPR.102

CRISPR, the Disruptor, NATURE (June 3, 2015), http://www.nature.com/news/crispr-the-disruptor1.17673.
89. Wang, supra note 88.
90. Jon Cohen, ‘Any Idiot Can Do It.’ Genome Editor CRISPR Could Put Mutant Mice in
Everyone’s Reach, SCI. MAG. (Nov. 3, 2016, 10:00 AM),
http://www.sciencemag.org/news/2016/11/any-idiot-can-do-it-genome-editor-crispr-could-put-mutantmice-everyones-reach.
91. Wang, supra note 88.
92. Id.
93. Id.
94. Monya Baker, Gene Editing at CRISPR Speed, 32 NATURE BIOTECH. 309, 309-12 (2014).
95. Id.
96. Haoyi Wang et al., One-Step Generation of Mice Carrying Mutations in Multiple Genes by
CRISPR/Cas-mediated Genome Engineering, 153 CELL 910, 910-18 (2013).
97. Id. at 914.
98. Id.
99. Baker, supra note 94, at 310.
100. Id.
101. Aileen Christensen, The “Miracle Method”: How CRISPR is Changing Biological Research,
ELSEVIER (Jan. 13, 2017), https://www.elsevier.com/connect/the-miracle-method-how-crispr-ischanging-biological-research; s. ee also Jorgensen, supra note 24; Doudna, supra note 30.
102. Cohen, supra note 90.
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CRISPR however, is not perfect. 103 It is known in the scientific
community to have problems with cutting DNA at off-target sites.104 One
researcher found as many as five mismatches when using CRISPR to cut
specific target locations. 105 Additionally, using CRISPR-induced HR to
integrate donor DNA has not been a simple feat.106 Despite the attachment
of homology arms at either side of the donor DNA, most cells usually repair
the DSB on its own through the NHEJ process.107 Some cells repair through
HR, by using the other chromatid as a template instead of the donor DNA.108
Hence, inducing HR in these types of cell lines can be difficult. 109
Researchers are trying to find ways to use CRISPR-induced HR to
successfully manipulate target cells. 110 Despite the numerous scientific
articles published on CRISPR, there is still so much researchers do not know
about CRISPR.111 Researchers will most likely begin their projects by using
CRISPR in order to screen target sequences because of the previouslymentioned reasons.112 However, after screening, researchers will most likely
utilize TALENs or ZFNs to build their projects. 113 In comparison to
CRISPR, TALENs and ZFNs not only have better specificity, but also have
the capacity to recognize longer DNA sequences.114
103. Baker, supra note 94, at 310.
104. Id.
105. Id.
106. Lin et al., Enhanced Homology-Directed Human Genome Engineering by Controlled Timing
of CRISPR/Cas9 Delivery, eLIFE, Dec. 2014, at 1, 1, available at
http://dx.doi.org/10.7554/eLife.04766.
107. CRISPR Frequently Asked Questions, IDT, https://www.idtdna.com/pages/docs/defaultsource/synthetic-biology/crispr_faq_043015.pdf?sfvrsn=2 (last visited May 13, 2017); see also Yoshimi
et al., ssODN-Mediated Knock-In with CRISPR-Cas for Large Genomic Regions in Zygotes, NATURE
COMMC’NS, Jan. 20, 2016 at 1, 2, available at doi:10.1038/ncomms10431.
108. See CRISPR Frequently Asked Questions, supra note 107; Lin et al., supra note 106, at 1.
109. PITCh-ing an Alternative Knock-In Strategy for TALENs and CRISPR/Cas9, GEN (Dec. 4,
2014), http://www.genengnews.com/gen-news-highlights/pitch-ing-an-alternative-knock-in-strategyfor-talens-and-crisprcas9/81250665.
110. Harvard, MGH Team Creates CRISPR/Cas9 Variant That Eliminates Off-Target Effects,
GENOMEWEB (Jan.6, 2016), https://www.genomeweb.com/gene-silencinggene-editing/harvard-mghteam-creates-crisprcas9-variant-eliminates-target-effects; Sandeep Ravindran, Eliminating CRISPRCas9’s Off-target Effects, BIOTECHNIQUES (Jan. 13, 2016),
http://www.biotechniques.com/news/Eliminating-CRISPR-Cas9s-Off-target-Effects/biotechniques362580.html#.WKP11_JfbIU.
111. Probing How CRISPR-Cas9 Works: Study Examines DNA Targeting Dynamics in Live Cells,
PHYS.ORG (Aug. 26, 2016), https://phys.org/news/2016-08-probing-crispr-cas9-dna-dynamicscells.html.
112. Baker, supra note 94, at 310-11.
113. Sarah Zhang, Everything You Need to Know About CRISPR, the New Tool That Edits DNA,
GIZMODO (May 5, 2015), http://gizmodo.com/everything-you-need-to-know-about-crispr-the-new-tool1702114381.
114. Id.
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D. CRISPR: Naturally-Occurring vs. Modified CRISPR Systems
CRISPR, that is the functions of CRISPR, is not new to the scientific
community.115 CRISPR is a naturally-occurring adaptive immune system of
select bacteria and archaea.116 CRISPR was initially discovered in 1987 by
researchers who were studying the bacteria E.coli.117 It was not until 2007
when scientists were able to prove the function of CRISPR by experimenting
on S. thermophilus, a bacterial strain used to convert milk into yogurt.118
There are actually three types of CRISPR systems that have been identified,
of which the type II system is the most studied. 119 The type II CRISPR
system, the simplest of the three systems, is the basis for the CRISPR
genome editing tool used by researchers today.120
In bacterium such as Escherichia coli, the type II CRISPR system
includes CRISPR arrays of short palindromic repeats known as CRISPR
repeats.121 These CRISPR repeats are separated by spacers, which contain
unique sequences known as protospacer sequences. 122 Each time the
bacterium is invaded by a foreign DNA, the type II CRISPR system
incorporates fragments of the invading DNA into these spacers.123 Hence,
the CRISPR array grows with every new protospacer sequence that is
inserted.124 The CRISPR arrays is transcribed into a precursor CRISPR RNA
known as pre-crRNA. 125 The pre-crRNA is processed into mature short
CRISPR RNAs (crRNAs).126 Each crRNA has “protospacer” regions, which
contain complementary sequences that match to a specific sequence in the

115. Jinek et al., supra note 13, at 816.
116. Id.; Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA MAG. (Feb. 6, 2015),
https://www.quantamagazine.org/20150206-crispr-dna-editor-bacteria.
117. Zimmer, supra note 116.
118. Id.
119. Jinek, supra note 13, at 816; Krzysztof Chylinski et al., Classification and Evolution of Type II
CRISPR-Cas Systems, 42 NUCLEIC ACIDS RES. 6091, 6091-105 (2014).
120. Chylinksi et al., supra note 119, at 6091
121. Devashish Rath et al., The CRISPR-Cas Immune System: Biology, Mechanisms and
Applications, 117 BIOCHIMIE 119, 119-20 (2015).
122. Id.; Sander & Joung, supra note 29, at 349 Figure 3.
123. Rath et al., supra note 121, at 119-20; Sander & Joung, supra note 29, at 349fig 3.; Zhang,
supra note 113.
124. Rath et al., supra note 121, at 119-20; Sander & Joung, supra note 29, at 349fig 3; Zhang,
supra note 113.
125. Rath et al., supra note 121, at 119-20; Sander & Joung, supra note 29, at 349fig 3; Zhang,
supra note 113.
126. Eric S. Lander, The Heroes of CRISPR, 164 CELL 18, 18-28 (2016). See also Rath et al., supra
note 121, at 119-20; Sander & Joung, supra note 29, at 349fig 3; Zhang, supra note 113.
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virus DNA.127 Each crRNA hybridizes with an additional RNA known as a
trans-activating CRISPR RNA (tracrRNA). 128 These 2 types of RNA
(crRNA and tracrRNA) then form a complex with a Cas9 nuclease.129 This
complex actively searches the cell for DNA that matches its protospacer
sequences.130 Therefore, when the same virus attacks again, the complex is
able to use the crRNA and tracrRNA to recognize the virus, and latch onto a
specific site of the invading viral DNA.131 After the matching protospacer
sequence of the complex binds with the corresponding target site of the
DNA, Cas9 will disable the virus by cutting the viral DNA. 132 The type II
CRISPR system not only allows the bacterium to remember, record, and
deactivate its foreign invaders, but also allows it to pass all its stored
information onto the next generation.133
The CRISPR system is the adaptive and inheritable immune system of
certain bacteria and archaea, which are prokaryotes. 134 Prokaryotes are
simple single-celled organisms that lack a nucleus.135 Instead, prokaryotic
cells have DNA in the form of a single circular chromosome.136 The CRISPR
system does not exist naturally in eukaryotic cells.137 Animals and plants are
eukaryotes.138 Eukaryotic cells have many features such as membrane-bound
organelles, which are not found in prokaryotic cells.139 However, the most
important distinction between prokaryotic and eukaryotic cells is that
eukaryotic cells have a membrane-bound nucleus, which stores the cell’s
genetic information.140 The genetic information of eukaryotic cells, DNA, is
organized in chromosomes, of which humans have 46.141
127. Sander & Joung, supra note 29, at 348.
128. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19 Figure 1.
129. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19, Figure 1.
130. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19, Figure 1.
131. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19, Figure 1; see
Jorgensen, supra note 24; Doudna, supra note 30.
132. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19, Figure 1; see
Jorgensen, supra note 24; Doudna, supra note 30.
133. Sander & Joung, supra note 29, at 348-49. Lander supra note 126, at 19, Figure 1; see
Jorgensen, supra note 24; Doudna, supra note 30.
134. Zimmer, supra note 116.
135. Biology-Structure of a Cell, KHANACADEMY,
https://www.khanacademy.org/science/biology/structure-of-a-cell/prokaryotic-and-eukaryoticcells/a/prokaryotic-cells (last visited Dec. 23, 2016).
136. Id.
137. Zimmer, supra note 116.
138. KHANACADEMY, supra note 135.
139. Id.
140. Id.
141. Id.
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In 2012, researchers successfully adapted the type II CRISPR system to
eukaryotic cells.142 Although the basic function of the naturally-occurring
type II CRISPR system is mirrored in the engineered CRISPR system, there
is a notable distinction between the two. 143 As previously mentioned, the
naturally-occurring CRISPR system involves a dual-RNA structure, which
consists of crRNA and tracrRNA. 144 Researchers from the Doudna and
Charpentier labs of the University of California, Berkeley (“UCB”) modified
the CRISPR system so that Cas9 can be used with a single RNA structure
instead of the dual-RNA structure found in nature.145 A single RNA-guided
Cas9 complex would allow researchers to program a single RNA to target
and cut specific sites in the human DNA.146 To create a single RNA structure,
UCB scientists connected the tracrRNA and crRNA together to create a
tracrRNA-crRNA chimera. 147 The majority of the engineered CRISPR
systems today utilize a guide RNA (“gRNA”) that is a chimeric RNA— a
fusion between a CRNA and part of the tracrRNA.148
The CRISPR genome editing technology has been used to produce
some of the most exciting advancements for geneticists in recent years.149
The potential uses of CRISPR for the advancement of human health is both
exciting and daunting. 150 The financial stake in this technology is
enormous.151 Numerous life science companies are offering CRISPR-related
products.152 CRISPR’s potential for the growth of the therapeutics market
has also attracted much interest from investors.153 All this excitement in the
scientific community however, cannot escape the concern surrounding the
intellectual property (IP) of the CRISPR technology.154

142. Jinek, supra note 13, at 816.
143. Sander & Joung, supra note 29, at 349 Figure 3.
144. Id.
145. Jinek, supra note 13, at 817-20.
146. Id. at 820.
147. Id.
148. Sander & Joung, supra note 29, at 349.
149. See Ledford, supra note 8; Fessenden, supra note 9; CLINICALTRIALS.GOV, supra note 11.
150. Ledford, supra note 88.
151. RnR Market Research, supra note 70.
152. Id.
153. Id.
154. Tony Fong, As CRISPR-Cas Technology Sets to Take Off, Uncertainty Swirls Around IP
Landscape, GENOMEWEB (June 18, 2014), https://www.genomeweb.com/rnai/crispr-cas9-technologysets-take-uncertainty-swirls-around-ip-landscape.
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II. CRISPR: RELEVANT §101 CASE LAW
CRISPR has been the subject of an intense patent dispute between Feng
Zhang of the Broad Institute and MIT (“Broad”) and Jennifer Doudna of the
University of California, Berkeley (“UCB”) as to who invented the
technology first.155 There is also another ownership dispute between Broad
and Rockefeller University as to who the inventors are of several other
CRISPR patents. 156 The United States Patent and Trademark Office
(“USPTO”) has issued 28 patents on the CRISPR technology as of 2016.157
Outside of the U.S., there is a patent dispute over Zhang’s European CRISPR
patents. 158 These aggressive ownership disputes illustrate the role patents
have in not only protecting an inventor’s work, but also in commercializing
technology.
The inventorship disputes surrounding CRISPR raise other patentrelated concerns such as patent validity.159 Because the USPTO has issued
patents as to CRISPR, it is hypothesized that invalidity disputes as to several
CRISPR patents will find their way to federal court. CRISPR has garnered a
lot of interest by scientists, research institutions, and companies—many who
would clearly benefit from using the technology unencumbered. Invalidity
disputes concerning the CRISPR patents will most likely be raised under 35
U.S.C. §102 (“§102”) for lack of novelty or under 35 U.S.C. §103 (“§103”)
for obviousness. 160 However, this paper will only evaluate the CRISPR
technology under a hypothetical 35 U.S.C. §101 dispute challenging patenteligible subject matter.
Currently, there is no dispute in federal court challenging the eligibility
of the CRISPR patents under 35 U.S.C. §101 (hereinafter “§101”). However,

155. Heidi Ledford, Bitter Fight Over CRISPR Patent Heats Up, NATURE (Jan. 12, 2016),
http://www.nature.com/news/bitter-fight-over-crispr-patent-heats-up-1.17961.
156. Kerry Grens, That Other CRISPR Patent Dispute, THE SCIENTIST (Aug. 31, 2016),
http://www.the-scientist.com/?articles.view/articleNo/46921/title/That-Other-CRISPR-Patent-Dispute.
157. Jacob S. Sherkow, Who Owns Gene Editing? Patents in the Time of CRISPR, BIOCHEMICAL
SOC’Y 26, 26-29 (2016), http://www.biochemist.org/bio/03803/0026/038030026.pdf.
158. Id.
159. Jennifer K. Wagner, The Patent Dispute Over Gene Editing Technologies, GENOMICS L. REP.
(Feb. 4, 2016), http://www.genomicslawreport.com/index.php/2016/02/04/the-patent-dispute-overgene-editing-technologies-the-broad-institute-inc-vs-the-regents-of-the-university-of-california; see
Kristin Beale, The CRISPR Patent Battle: Who Will be “Cut” Out of Patent Rights to One of the
Greatest Scientific Discoveries of Our Generation, B.C. INTELL. PROP. & TECH. F. (2015),
http://bcipt.org; Benjamin C. Tuttle, The Failure to Preserve CRISPR-Cas9’s Patentability Post Myriad
and Alice, 98 J. PAT. & TRADEMARK OFF. SOC’Y 391, 404 (2016).
160. This is hypothesized based on the current interference proceeding between Broad and UCB; s.
ee Isobel Finnie & Catherine Williamson, CRISPR Patent Wars, GEN (Feb. 6, 2017),
http://www.genengnews.com/gen-exclusives/crispr-patent-wars/77900842.
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recent Supreme Court decisions on §101 have affected the landscape for life
science patents. 161 By evaluating the CRISPR technology under a
hypothetical §101 dispute in federal court, this paper intends illustrate how
the modern §101 framework is applied to life science inventions.
A. Patents: The Basics
A patent is a property right the government grants to an inventor for a
limited period of time—generally, 20 years from the effective filing date of
the patent application.162 A patent does not grant an inventor the exclusive
right to make, use, offer for sale, sell, or import the invention.163 Rather, a
patent grants an inventor the right to exclude others from “making, using,
offering for sale, or selling” the invention in the U.S. or “importing” the
invention into the country.164 A patent’s “claims” establish the scope of the
invention, and define the exclusive right granted to the inventor.165 Hence,
when a patent dispute is in court because of issues such as invalidity or
infringement, it is the claims that are litigated—the claims are at stake.166
The power to grant patents is found in the United States Constitution in
Art. I, Sec. 8, Clause 8, also known as the Intellectual Property Clause. This
clause grants Congress the power “to promote the progress of science and
useful arts, by securing for limited times to authors and inventors the
exclusive right to their respective writings and discoveries.”167 Pursuant to
this authority, Congress enacted the U.S. Patent Act (“Patent Act”).168 The
Patent Act, which is found in Title 35 of the United States Code, authorizes
the USPTO to establish patent rules not inconsistent with the law. 169 The
USPTO examines patent applications and issues patents.170

161. Alice Corp. v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014); Ass’n for Molecular Pathology
v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013); Mayo Collaborative Servs. v. Prometheus
Labs., Inc., 566 U.S. 66, 71 (2012).
162. General Information Concerning Patents, USPTO (Oct. 2015),
https://www.uspto.gov/patents-getting-started/general-information-concerning-patents (last visited Feb.
14, 2017).
163. Id.
164. 35 U.S.C. §154(a)(1) (2017).
165. USPTO, supra note 162.
166. Id.
167. U.S. CONST. art. I, §8, cl. 8
168. USPTO, supra note 162.
169. Id.
170. Id.
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The 5 primary requirements for patentability are as follows: patentable
subject matter, utility, novelty, non-obviousness, and enablement.171 These
requirements are all found in 35 U.S.C. §§101, 102, 103, and 112. After a
patent has been issued, its validity can be challenged (on any of the grounds
previously mentioned) in special proceedings at the USPTO or in federal
court.172 It is worth briefly mentioning that there are two different standards
that govern patent claims. 173 Prior to issuance, the claims in a patent
application are examined by the USPTO under a broadest reasonable
interpretation (BRI) standard. 174 In contrast, patent claims at dispute in
federal court are construed in accordance to a plain meaning standard.175
B. Subject Matter Eligibility Under 35 U.S.C. §101
35 U.S.C. §101 (“§101”) states that anyone who “invents or discovers
any new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain a patent
therefor, subject to the conditions and requirements of this title.”176 Hence,
only inventions that fall within the patent eligible categories: “process,
machine, manufacture, or composition of matter” are eligible for patent
protection.177 The Supreme Court, traditionally, has interpreted §101 to also
include “implicit exception[s]” to 3 broad principles: laws of nature, natural
phenomena, and abstract idea. 178 Inventions directed to one of these
judicially recognized exceptions (referred to as “judicial exceptions”) have
long been held by courts as patent ineligible.179 The discovery of a law of
nature, physical phenomena, or abstract idea itself is not patentable because
these are “manifestations of nature which are free to all men and reversed
exclusively to none.”180 Hence, the discovery of a new mineral or plant found

171. Patent, LEGAL INFO. INST., https://www.law.cornell.edu/wex/patent (last visited on Dec. 23,
2016).
172. MPEP §1216 (“Judicial Review”) (9th ed., rev. 7 Nov. 2015) (hereinafter “MPEP”).
173. MPEP §2111 (“Claim Interpretation; Broadest Reasonable Interpretation”).
174. Id.; see also Fanelli Haag, Practical Implications of the Two Claim Construction Standards in
the Post-AIA World, LEXOLOGY, July 16, 2015,
http://www.lexology.com/library/detail.aspx?g=260f7965-7f9c-463d-859f-7d5c6b6a7575.
175. Id. (this is also known as the Phillips standard.).
176. 35 U.S.C. § 101 (2012).
177. Id.
178. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013)
(quoting Mayo Collaborative Servs. v. Prometheus Labs, Inc., 566 U.S. 66, 70-71 (2012)).
179. Id.
180. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (quoting Funk Brothers Seed. Co. v. Kalo
Inoculant Co., 333 U.S. 127, 130 (1948)).
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in nature is not patentable.181 This also explains why celebrated discoveries
such as Einstein’s formula E=mc2 and Newton’s law of gravity were not
patentable.182
The patent system exists to award inventive activity and encourage
innovation.183 Hence, patents are not meant to give a select few the power to
monopolize knowledge belonging in the public domain. On the other hand,
too narrow of an interpretation of §101 could impede innovation. 184 In
recognizing the dangers of interpreting the judicial exceptions too broadly,
the Supreme Court has long acknowledged that “all inventions at some level
embody, use, reflect, rest upon, or apply laws of nature, natural phenomena,
or abstract ideas.” 185 Thus, the Supreme Court has held that the mere
recitation of a judicial exception does not make a claim ineligible for
patenting.186 Rather, it is the application of the judicial exception that needs
to be examined.187
C. Pre-Alice: Relevant Supreme Court Decisions
Before applying the modern framework to a hypothetical §101 subject
matter eligibility CRISPR dispute, it is helpful to review several relevant
Supreme Court decisions. Prior to Alice Corp. Pty. Ltd. v. CLS Bank Int’l,188
(hereinafter “Alice”) the Supreme Court had issued several subject matter
eligibility decisions pertinent to the life sciences field. In Diamond v.
Chakrabarty (hereinafter “Chakrabarty”), the Supreme Court held that
living organisms are patentable subject matter under §101. 189 In
Chakrabarty, a super oil-eating bacterium was at issue.190 Four strains of oileating bacteria that exist in nature, each possess the ability to digest different
components of the oil.191 These bacteria have plasmids, which are rings of

181.
182.
183.
184.

Id.
Id.
U.S. CONST. art. I, § 8, cl. 8.
Marshall Phelps, Do Patents Really Promote Innovation? A Response to the Economist,
FORBES, Sept. 16, 2015, http://www.forbes.com/sites/marshallphelps/2015/09/16/do-patents-reallypromote-innovation-a-response-to-the-economist/3/#62d9e6db32b5. See; see also E. Richard Gold et
al., Are Patents Impeding Medical Care and Innovation?, 7 PLOS MED e1000208 (2010).
185. Mayo Collaborative Servs., v. Prometheus Labs, Inc., 566 U.S. 66, 71. (2012).
186. Id. at 71-72.
187. Id.
188. Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014).
189. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
190. Id. at 305.
191. This Week in Science History- the First Genetic Patent, NAKED SCIENTIST, Mar. 30, 2009,
http://www.thenakedscientists.com/articles/interviews/week-science-history-first-genetic-patent.

426

CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY

Vol 16:408

DNA that code for the proteins that eat the oil.192 Dr. Chakrabarty combined
the four plasmids into a single bacterium, effectively creating a new species
of bacteria.193 In a 5-4 decision, the Supreme Court held that a live, humanmade microorganism was patentable subject matter under §101 because the
oil-eating property of the genetically modified bacterium was not possessed
by any naturally occurring bacteria.194
The Chakrabarty decision laid the foundation for allowing the patenting
of genetically modified living organisms such as transgenic mice. 195 It is
important to note that patent claims directed to human organisms, such as
embryos and fetuses, have never been patent eligible subject matter.196 In
Mayo Collaborative Servs. v. Prometheus Labs., Inc (hereinafter “Mayo”),
the Supreme Court laid out the inventive concept requirement seen in the
second step of the Alice framework.197 The invention at issue in Mayo was a
personalized medicine dosing process. 198 Researchers discovered natural
correlations between specific metabolite levels in the body and a dosage
range for the drug thiopurine.199 The invention identified methods reciting
steps such as “administering” a drug to a patient, “determining” the level of
metabolite in the patient, and adjusting the dosage based on the correlation
discovered by the researchers.200 In a 9-0 decision, the Supreme Court held
that the dosing process was not patentable subject matter under §101 because
the correlation claimed was a law of nature.201 Further, the Court held that
the additional steps, “when viewed as a whole,” were not enough to
transform the judicial exception into a patentable application of it.202

192. Id.
193. Id.
194. Id.; Diamond, 447 U.S. at 309-10.
195. This Week in Science History- the First Genetic Patent, supra note 191.
196. Leahy-Smith America Invents Act, Pub. L. No. 112-29, §33(a), 125 Stat. 284, 340 (2011)
(“Notwithstanding any other provision of the law, no patent may issue on a claim directed to or
encompassing a human organism.”); see also Memorandum from Robert W. Bahr to Patent Examining
Corps (Sept. 20, 2011), (available at
https://www.uspto.gov/sites/default/files/aia_implementation/human-organism-memo.pdf).
197. Alice Corp. Pty. Ltd., v. CLS Bank Int’l, 134 S. Ct. 2347, 2357-58 (2014).
198. Mayo Collaborative Servs., v. Prometheus Labs, Inc., 566 U.S. 66, 72 (2012); see also Dennis
Crouch, Mayo v. Prometheus: Natural Process + Known Elements = Normally No Patent, PATENTLYO,
Mar. 20, 2012, http://patentlyo.com/patent/2012/03/mayo-v-prometheus-natural-process-knownelements-normally-no-patent.html; Judith Kim & Scott Schaller, After Alice: The Two-step Rule, LSIPR
NEWSLETTER, 2015, at 10-13, http://www.skgf.com/uploads/1378/doc/LSIPR_Jan15_AfterALice.pdf.
199. Id.
200. Mayo Collaborative Servs., 566 U.S. at 71-72.
201. Id. at 92.
202. Id. at 80.
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In Ass’n for Molecular Pathology v. Myriad Genetics, Inc. (hereinafter
“Myriad”), the Supreme Court held that a “naturally-occurring DNA
segment” is not patent eligible merely because its covalent bonds were
severed in order to isolate the DNA segment.203 Rather, an isolated segment
of naturally occurring DNA is a patent ineligible product of nature.204 The
Court also held that complementary DNA (cDNA) is patent eligible subject
matter. 205 The Court reasoned that cDNA, a synthetic version of DNA
created from mRNA, “contains only the exons that occur in DNA, omitting
the intervening introns.”206 Exons are the expressed sequences of DNA that
code for protein whereas intron are non-expressing sequences of DNA that
do not code.207 The rationale behind the Myriad decision is based on the fact
that DNA stores genetic information. 208 Although isolated DNA and
naturally occurring DNA have chemical differences due to the breaking of
the covalent bonds, the genetic information stored in the isolated DNA is the
same when compared to its naturally occurring state. 209 The breaking of
covalent bonds “does not change the information-transmitting quality.”210
However, cDNA is created in a lab by removing introns from naturally
occurring genomic DNA through known lab procedures.211 Hence, because
cDNA is not naturally occurring in its natural environment (human cells), it
is patent eligible.212 This decision has sparked much debate in the scientific
community as many scientists believe that the difference between cDNA and
naturally occurring genomic DNA (gDNA) are trivial.213
Lastly, it is worth pointing out In re Roslin Inst. (Edinburgh),
hereinafter “Roslin.”214 This decision from the U.S. Court of Appeals for the

203. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2116 (2013).
204. Id. at 2111.
205. Id.
206. Id. at 2109.
207. Id.
208. Jason Rantanen, Myriad: Isolated DNA Out, cDNA In, PATENTLYO, June 13, 2013,
http://patentlyo.com/patent/2013/06/myriad-isolated-dna-out-cdna-in.html.
209. Id.
210. Ass’n for Molecular Pathology, 133 S. Ct. at 2115.
211. Id.
212. Id.
213. Noam Prywes, The Supreme Court’s Sketchy Science, SLATE, June 2013,
http://www.slate.com/articles/health_and_science/science/2013/06/supreme_court_patent_case_science
_the_justices_misunderstand_molecular_biology.html; Megan Krench, New Supreme Court Decision
Rules that cDNA is Patentable, SCIENTIFIC AMERICAN, July 9, 2013,
https://blogs.scientificamerican.com/guest-blog/new-supreme-court-decision-rules-that-cdna-ispatentablewhat-it-means-for-research-and-genetic-testing; see also Rantanen, supra note 208.
214. In re Roslin Inst. (Edinburgh), 750 F.3d 1333, 1337 (Fed. Cir. 2014).
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Federal Circuit (hereinafter “Federal Circuit”) was issued one month before
the Supreme Court’s Alice decision.215 In Roslin, the Federal Circuit held that
Dolly the cloned sheep, effectively any genetic clone, is not patentable
subject matter under §101.216 Dolly was cloned from an adult somatic cell.217
The method of cloning mammals by using somatic cells was patented, and
not at issue in this case.218 At issue, rather, was whether the products of the
cloning method could be patented.219 The Roslin court compared the claimed
clones to the isolated DNA in Myriad and reasoned that no genetic
information (of the clones) was created or altered.220 The court also pointed
out that “the genetic structure of the DNA used to make [the] clones” was
not created or altered in any way. 221 In rejecting the patent claims, the
Federal Circuit reasoned that Dolly, the claimed subject matter, did not
possess markedly different characteristics from her donor parent.222 Dolly
was an “exact genetic replica” of her donor parent, and therefore patent
ineligible.223
D. The Modern Approach on §101 Analysis: Alice
At the outset of every §101 subject matter eligibility inquiry, it is
necessary to ask if the invention falls within one of the 4 patent-eligible
categories.224 If the invention does not have any claims directed to either a
process, machine, manufacture, or composition of matter, the inquiry goes
no further.225 The invention is not eligible for patent protection.226 In Alice,
the Supreme Court articulated a 2-part framework for distinguishing patents
that claim a patent-ineligible judicial exception from those that claim a

215. Id. at 1333.
216. Id. at 1337.
217. Gene Quinn, Dolly the Cloned Sheep Not Patentable in the U.S., IPWATCHDOG, May 8, 2014,
http://www.ipwatchdog.com/2014/05/08/dolly-the-cloned-sheep-not-patentable-in-the-u-s/id=49471.
218. Id.
219. In re Roslin Inst. (Edinburgh), 750 F.3d at 1333.
220. Id. at 1337.
221. Id.
222. Id. at 1337-39.
223. Quinn, supra note 217.
224. Alice Corp. Pty. Ltd., v. CLS Bank Int’l, 134 S. Ct. 2347, 2355 (2014).
225. See Id.; 2014 Interim Eligibility Guidance Quick Reference Sheet, USPTO Examination
Guidance and Training Materials (Dec. 2014),
https://www.uspto.gov/patents/law/exam/2014_eligibility_qrs.pdf.
226. See Alice Corp. Pty. Ltd., 134 S. Ct. at 2355; 2014 see Interim Eligibility Guidance Quick
Reference Sheet, supra note 225.
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patent-eligible application of the exceptions.227 The Alice decision focused
on the judicial exception of abstract ideas in the context of computer-related
inventions.228 However, its framework was derived in large part from Mayo,
where the Supreme Court held methods of administering a drug based on
specific levels of a metabolite to be patent ineligible.229
The first step of the Alice framework is to determine “whether the
claims at issue are directed to a patent-ineligible concept.” 230 It is well
established that products of nature, as opposed to those of human
intervention, fall within the judicial exceptions.231 Therefore, inventions that
encompass a product derived from natural sources (known as “nature-based
products”) are analyzed more closely under this first step.232 Nature-based
products, like CRISPR, must possess “markedly different characteristics”
from any found in nature in order to be patent eligible.233 The nature-based
product limitation is compared to its naturally-occurring counterpart found
in its natural state.234 Types of characteristics to consider when determining
“markedly different characteristics” include, but are not limited to the
following: biological functions or activities, chemical and physical
properties, phenotype, and structure and form.235 If the nature-based product
limitation has markedly different characteristics, the patent claim at issue is
patent eligible under §101.236 The eligibility inquiry stops here.237
If, however, the answer is no (there are no markedly different
characteristics), the eligibility inquiry continues onto the second step.238 The
second step of the Alice framework is to determine whether the claim recites
any “additional elements [that] ‘transform the nature of the claim’ into a
patent-eligible application.” 239 There needs to be an inventive concept

227. See Alice Corp. Pty. Ltd., 134 S. Ct. at 2355; see 2014 Interim Eligibility Guidance Quick
Reference Sheet, supra note 225.
228. Alice Corp. Pty. Ltd., 134 S. Ct. at 2357.
229. Mayo Collaborative Servs., 566 U.S. at 71-72.
230. Alice Corp. Pty. Ltd., 134 S. Ct. at 2355.
231. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225.
232. Id.; Alice Corp. Pty. Ltd., 134 S. Ct. at 2355.
233. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225.
234. Id.
235. Analyzing Nature-based Products Slides, USPTO Training Materials on Subject Matter
Eligibility, 1-39, 9 (Feb. 2015), available at
https://www.uspto.gov/sites/default/files/documents/101%20JE%20training%20NatureBased%20Products%20Module.pdf
236. 2014 Interim Eligibility Guidance Quick Reference Sheet, supra note 225.
237. Id.
238. Id.
239. Alice Corp. Pty. Ltd., 134 S. Ct. at 2357 (quoting Mayo Collaborative Servs., 566 U.S. at 78).
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sufficient to guarantee that the claim “amounts to significantly more” than
the judicial exception itself.240 In determining if there is an inventive concept,
all the claim elements, must be considered “both individually and in
combination[.]”241 If there is an inventive concept, the claims at issue are
patent eligible under §101.242 If the patent claims instead recite additional
elements that involve “well-understood, routine, conventional activity,” the
claims are patent ineligible.243
E. Post-Alice Decisions: Applying Alice
Since the Supreme Court’s Alice decision in 2014, the Federal Circuit
has issued several §101 subject matter eligibility decisions, of which two are
relevant to the life sciences field.244 These decisions provide some guidance
on how the Alice framework is being applied to life science inventions in
federal court. First, the Federal Circuit held in Rapid Litig. Mgmt. v.
CellzDirect, Inc. (“CellzDirect”) that an improved process of cryopreserving
hepatocyte cells was patent eligible under §101.245 Hepatocytes, a type of
liver cell, are preserved for future use in a process known as
cryopreservation. 246 Here the inventors discovered that “some fraction of
hepatocytes are capable of surviving multiple freeze-thaw cycles.”247 Instead
of using frozen cells once, scientists could refreeze the cells and use them
again.248 The patent claimed an improved process which recited steps such
as “subjecting” previously frozen cells to a known technique to separate
viable and non-viable cells, “recovering” the viable cells, and “refreezing”
these cells. 249 The claims specified that this preparation could be used
immediately after thawing, exhibiting 70% viability.250
In applying the first step of the Alice framework, the Federal Circuit
held that the claims were not directed to a patent ineligible judicial

240. Id.
241. Id. at 2357 n.3.
242. Id. at 2355.
243. Id. at 2359. (quoting Mayo Collaborative Servs., 566 U.S. at 73).
244. Rapid Litig. Mgmt v. CellzDirect, Inc., 827 F.3d 1042 (2016); Ariosa Diagnostics, Inc. v.
Sequenom, Inc., 788 F.3d 1371 (2015).
245. 827 F.3d at 1050-51.
246. Id. at 1045.
247. Id.
248. Id.
249. Id.
250. Id.
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exception. 251 The court reasoned that the inventors did not patent their
natural discovery, but instead used it “to create a new and improved way of
preserving hepatocyte cells for later use.”252 The Federal Circuit emphasized
that in asking if a claim is “directed to” a judicial exception, “merely
identify[ing] a patent-ineligible concept” “is not enough.”253 Rather, “the end
result of the process,” as a whole must be an ineligible judicial exception.254
The end result here was more than an “observation or detection of the ability
of hepatocytes to survive multiple freeze-thaw cycles”—it was an improved
process “of producing a desired preparation.”255 Because the patent claims
were not directed to a judicial exception, the eligibility inquiry did not move
on to the second step.256
Second, the Supreme Court denied a petition for writ of certiorari in
Sequenom, Inc. v. Ariosa Diagnostics, Inc. 257 (hereinafter “Sequenom”),
leaving the Federal Circuit decision in place.258 In Sequenom, the Federal
Circuit held a fetal DNA diagnostic method to be patent ineligible subject
matter under §101. 259 Scientists discovered the presence of cell-free fetal
DNA (cffDNA) in the bloodstream of pregnant women.260 The idea was that
fetal DNA could be accessed separately from the maternal DNA by linking
it to the paternal DNA portion of the cffDNA. 261 This discovery made it
possible to create a non-invasive prenatal test to screen for genetic defects in
the fetus. 262 The patent claimed a method, which recited two steps:
“amplifying” a sample of cffDNA taken from a pregnant woman, and
“detecting” the paternally-inherited portion of DNA in the cffDNA.263
In applying the first step of the Alice framework, the Federal Circuit
held that the claimed method was directed to a patent ineligible natural

251. Id. at 1049-51.
252. Id. at 1048; see also Memorandum on Recent Subject Matter Eligibility Rulings from Robert
W. Bahr to Patent Examining Corps (July 14, 2016), available at
https://www.uspto.gov/sites/default/files/documents/memo_rlm-sequenom.pdf.
253. Rapid Litig. Mgmt., 827 F.3d at 1050.
254. Id. at 1048.
255. Id.
256. Id. at 1048-49.
257. Sequenom, Inc. v. Ariosa Diagnostics, Inc., 2016 U.S. LEXIS 4087 (June 27, 2016).
258. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (2015).
259. Id. at 1376.
260. Id.
261. Dennis Crouch, Federal Circuit Reluctantly Affirms Ariosa v. Sequenom and Denies En Banc
Rehearing, PATENTLYO (Dec. 3, 2015), http://patentlyo.com/patent/2015/12/reluctantly-sequenomrehearing.html.
262. Id.
263. Ariosa Diagnostics, Inc., 788 F.3d at 1373-74.
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phenomena.264 In applying the second step, the court held that the method
did not recite an inventive concept that transformed the judicial exception
(presence of cffDNA in maternal bloodstream) into a patent eligible
application of the exception.265 The court compared the invention to Mayo
and reasoned that the additional “amplifying” and “detecting” steps were
“well-understood, routine, and conventional activity” at the time the patent
application was filed.266 This decision was not unexpected.267 However, it
was not well-received by the life sciences field,268 especially after the court
acknowledged that the discovery “may have been a significant contribution
to the medical field.”269 Many in the life sciences field believe that under the
Intellectual Property Clause and patent laws, new and useful discoveries
should be eligible for patent protection.270
III. CRISPR: HYPOTHETICAL §101 PATENT INVALIDITY DISPUTE
As previously mentioned, there are 28 U.S. patents on the CRISPR
technology as of February 2016.271 These patents all claim different aspects
and variations of the CRISPR technology.272 Instead of applying the §101
framework to each of the patents, it would be in the best interest of this
paper’s purpose to focus on the patent claims that cover the core CRISPR
technology. This paper will apply the §101 analysis to the single count in the
current USPTO patent interference proceeding between Doudna (UCB) and
Zhang (Broad).273 The one count in dispute is as follows:274
A method, in a eukaryotic cell, of cleaving or editing a target DNA molecule or
modulating transcription of at least one gene encoded thereon, the method
comprising:

264. Id. at 1376.
265. Id. at 1377-79. See also Memorandum on Recent Subject Matter Eligibility Rulings from
Robert W. Bahr to Patent Examining Corps, supra note 252.
266. Ariosa Diagnostics, Inc., 788 F.3d at 1337.
267. Crouch, supra note 261.
268. Id.
269. Ariosa Diagnostics, Inc., 788 F.3d at 1379-80.
270. Crouch, supra note 261.
271. CRISPR Patents and Licensing Information, BROAD INST.,
https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-patents-and-licensinginformation (last visited Feb. 14, 2017).
272. Knut J Egelie et al., The Emerging Patent Landscape of CRISPR-Cas Gene Editing
Technology, 34 NATURE BIOTECH. 1025, 1025-31 (2016).
273. USPTO Patent Interference No. 106048 (public interference documents can be accessed at
https://acts.uspto.gov/ifiling/PublicView.jsp).
274. Notice to Declare Interference, 1-17 (Jan. 11, 2016) for USPTO Patent Interference No.
106048.
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contacting, in a eukaryotic cell, a target DNA molecule having a target sequence
with an engineered and/or non-naturally-occurring Type II Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas)
(CRISPR-Cas) system comprising:
a) a DNA-targeting RNA comprising
i) a targeter-RNA or guide sequence that hybridizes with the target
sequence, and
ii) an activator-RNA or tracr sequence that hybridizes with the targeterRNA to form a double-stranded RNA duplex of a protein-binding segment,
and
b) a Cas9 protein,
wherein the DNA-targeting RNA forms a complex with the Cas9 protein, thereby
targeting the Cas9 protein to the target DNA molecule, whereby said target DNA
molecule is cleaved or edited or transcription of at least one gene encoded by the
target DNA molecule is modulated.275

A count is a best described as a “hypothetical patent claim” that covers
the overlapping invention.276 In the CRISPR interference proceeding, a 3judge panel compared UCB’s pending patent application (No. 13/842,859)
to the Broad’s 12 U.S. patents and found that they overlapped as to the one
count mentioned above.277 At issue is a DNA-editing method.278 The method
recites one step of “contacting” a target DNA molecule in a eukaryotic cell
with a Type II CRISPR system.279 The claimed CRISPR system is described
as essentially having two components: a guide RNA (the “DNA-targeting
RNA”) made up of a targeter and an activator RNA, and a Cas9 protein.280
The guide RNA (gRNA) is described as forming a complex with the Cas9
protein to cut the target DNA molecule.281

275.
276.
277.
278.
279.
280.
281.

Id. at 10-11.
Sherkow, supra note 157 at 27.
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A. CRISPR: Applying the §101 Alice Framework
Before applying the Alice framework, the patent claim in dispute needs
to fall within one of the four subject matter eligible categories. Here, a
process claim is in dispute. The first step in Alice asks whether the claim at
issue is directed to a patent-ineligible judicial exception. Per the USPTO
training materials, process claims are not subject to the markedly different
characteristics analysis used for nature-based products unless the process
claim is “drafted in such a way that there is no difference in substance from
a product claim to a nature-based product.”282 Here, the only method step is
arguably the “contacting” step. The rest of the claim is directed to a naturebased product limitation because the type II CRISPR system is a naturally
occurring phenomena in select prokaryotes. Hence, this CRISPR system
described in the patent claim needs to be examined under the “markedly
different characteristics” analysis.283
The claimed CRISPR system possesses characteristics that are
markedly different from the naturally-occurring counterpart found in select
bacteria. Under the analysis, markedly different characteristics based on
properties such as structure and function need to be identified. First, the
structure of the “DNA-targeting RNA”284 in the claimed CRISPR system is
different from the structure found in nature. In the naturally-occurring
CRISPR system, the “DNA-targeting RNA” 285 is a dual RNA structure
comprising of crRNA, which is the targeter RNA, and tracrRNA, which is
the activator RNA. The “DNA-targeting RNA” found in the claimed
CRISPR system is a single RNA structure. This single RNA structure
(gRNA), is a fusion of the crRNA and tracrRNA, which is naturally found
in the CRISPR system of select prokaryotes.286 Researchers implementing
the type II CRISPR system design gRNA using segments of crRNA and
tracrRNA.287 However, even though the naturally-occurring components are
the same, the amount of each component used is different.288 The claimed

282. Analyzing Nature-based Products Slides, supra note 235 at 6.
283. It is important to note that the USPTO guidance and training materials are used by examiners
at the USPTO when examining claims during patent prosecution. In a subject matter eligibility dispute
at federal court, a judge may or may not refer to the USPTO’s guidance and training materials.
284. Notice to Declare Interference, supra note 274, at 11.
285. Id.
286. Jinek, supra note 13, at 819-20.
287. Id.; Patrick D. Hsu, DNA Targeting Specificity of RNA-guided Cas9 Nucleases, 31 NATURE
BIOTECH. 827, 827-32 (2016).
288. Jinek, supra note 13, at 819-20; Hsu, supra note 287, at 827-32.
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CRISPR system is used in different eukaryotic cell lines.289 Based on the cell
line and need, truncated versions of crRNA and tracrRNA can be used.290
The rationale in Myriad seems to emphasis the importance of structural
differences over chemical differences in determining whether a nature-based
product is markedly different from its naturally-occurring counterpart.291 In
Myriad, the Supreme Court held that “Myriad did not create or alter either
the genetic information encoded in the BRCA1 and BRCA2 genes or the
genetic structure of the DNA.”292 Similar to the cDNA of Myriad, which was
held to be patent eligible because of the removal of naturally present
introns 293 , the fusion of crRNA and tracrRNA here into a single RNA
structure is a notable structural difference.
Second, the function of the claimed CRISPR system is different from
the function of its naturally-occurring counterpart. The CRISPR system of
bacteria such as Streptococcus pyogenes, acts as an immune system to help
the bacteria defend against foreign invaders, such as viruses.294 The type II
CRISPR system incorporates segments of the invading virus DNA into its
protospacer regions. 295 Further, naturally-occurring CRISPR of some
bacteria wait until the foreign invader starts replicates before attacking.296 In
contrast, the claimed CRISPR system is not used as an immune system, but
as a genome editing tool. Hence its function is different.
Also, instead of inserting a piece of foreign DNA into its system to
defend against future attacks, the claimed CRISPR system is inserted into
eukaryotic cells in order to recognize and cut target DNA sequences. Further,
the purpose of modifying the dual RNA structure to a single RNA structure
is to deliver foreign DNA (i.e. specific sequences of DNA) to specific target
sites in the genome. 297 Programming a single RNA structure to target
different DNA sequences is a markedly different characteristic consistent
with the rationale of Myriad and Roslin. In Roslin, the Federal Circuit held
that the clones did not have “markedly different characteristics from the
donor animals” because the genetic information of the clones remained

289. Jinek, supra note 13, at 819-20; Hsu, supra note 287, at 827-32.
290. Jinek, supra note 13, at 819-20; Hsu, supra note 287, at 827-32.
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292. Ass’n for Molecular Pathology 133 S. Ct. at 2109-10.
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296. A Newly Discovered Form of Immunity Helps Explain Viruses, PHYS.ORG (Feb. 4, 2016),
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unchanged.298 Unlike the clones in Roslin, the genetic information of the
“DNA-targeting RNA”299 in the claimed CRISPR system is different from
its naturally-occurring counterpart because each “DNA-targeting RNA”300
can incorporate different DNA sequences to target a specific sequence in the
genome.
A narrow interpretation of recent case law has led some to conclude that
the claimed CRISPR system does not possess markedly different
characteristics from its naturally-occurring counterpart.301 In The Failure to
Preserve CRISPR-Cas9’s Patentability Post Myriad and Alice, Tuttle points
to the fact that the same Cas9 nuclease, crRNA, and tracrRNA found in
nature are used in the engineered CRISPR system.302 Further, Tuttle points
out that in order to cut at target DNA sites, the “DNA-targeting RNA”303
needs to incorporate a matching sequence that is identical to its naturallyoccurring counterpart.304 He elaborates that if this does not occur, the targeter
RNA of the “DNA-targeting RNA” 305 will not recognize and bind to its
target DNA sequence.306 Although these are all valid points to be made, the
Federal Circuit emphasized in the recent CellzDirect decision that the patent
claim as a whole, that is, “the end result of the process,” needs to be directed
to a judicial exception in the first Alice step.307 Although the type II CRISPR
system itself is a natural phenomenon, and the individual components of the
claimed CRISPR system can be found in nature, the claimed system as a
whole is not naturally found in prokaryotes or eukaryotes. A court that finds
the patent claim at issue to not be directed to a patent ineligible judicial
exception will stop the eligibility inquiry here, and hold that the claim
covering the CRISPR system is patent eligible subject matter under §101.308
If a court instead finds that the claimed CRISPR system contains no
markedly different characteristics from its naturally-occurring counterpart,
the eligibility inquiry will continue onto the second step under Alice. The

298. In re Roslin Inst. (Edinburgh), 750 F.3d at 1339.
299. Notice to Declare Interference, supra note 274 at 11.
300. Id.
301. Tuttle, supra note 159 at 404 (“Given the recent case law, an application of the markedlydifferent analysis to each CRISPR component would likely lead a court to conclude that the claimed
products-of-nature are not patent eligible.”).
302. Id. at 404-05.
303. Notice to Declare Interference, supra note 274 at 11.
304. Tuttle, supra note 159, at 404.
305. Notice to Declare Interference, supra note 274 at 11.
306. Tuttle, supra note 159, at 404.
307. Rapid Litig. Mgmt. v. CellzDirect, Inc, 827 F.3d 1042, 1048 (2016).
308. Id. at 1047.
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second step asks whether the patent claim recites additional elements that
transform the judicial exception into a patent-eligible application of the
exception (here, nature-based product).309 In short, under this second step,
there needs to be an inventive concept.310 If a court did not find the patent
claim covering the CRISPR system to be patent eligible under the first step
of Alice, they will most certainly find it to eligible under the second step.
First the patent claim at issue takes the naturally-occurring type II CRISPR
system and implements it in a eukaryotic cell. Eukaryotic cells do not
naturally have a CRISPR system. 311 Scientific literature from the Doudna
(UCB) and Zhang (Broad) labs (as well as earlier scientists) illustrate that
getting the naturally-found CRISPR system (dual RNA structure) to work in
eukaryotic cells required human intervention.312 Both the Doudna and Zhang
publications illustrate the experiments both labs conducted in order to get the
naturally-occurring CRISPR system (dual RNA structure) and claimed
CRISPR system (single RNA structure) to properly function in eukaryotic
cells.313
Second, scientists connected crRNA and tracrRNA to form a single
RNA structure to use the claimed CRISPR system as a genome editing tool
in eukaryotic cells.314 This is similar to the improved process of preserving
hepatocyte cells in CellzDirect. In CellzDirect, scientists discovered that a
fraction of frozen hepatocyte cells could be reused again. 315 They
subsequently patented an application of that discovery—an improved
method of preserving hepatocytes for later use.316 The Federal Circuit held
that the scientists did not patent the discovery, but rather “as the first party
with knowledge of the cells’ ability, they were ‘in an excellent position to
claim applications of that knowledge.’”317 In the same way, scientists at UCB
and Broad discovered the function and mechanisms of the type II CRISPR
system as an adaptive immune system. Instead of patenting this discovery,
scientists patented applications of this discovery by claiming a genome
editing tool. Hence, the patent claim at issue is arguably different from the
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310. Alice Corp. Pty. Ltd., 134 S. Ct. at 2355.
311. Jinek, supra note 13, at 819.
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personalized dosing process of Mayo as well as the prenatal genetic
screening process of Sequenom. Unlike Mayo and Sequenom, the scientists
here did not stop after discovering the natural phenomena, but worked to
invent a patent eligible application of the phenomena. Further, the Supreme
Court emphasized in Alice that the claim elements in the second step of the
analysis need to be considered “both individually and in combination” as a
whole.318 Therefore, a court could reasonably conclude that the patent claim
at issue, when considered as a whole, is a patent-eligible application of a
judicial exception. Hence, the single count of the interference proceeding
would be patent eligible subject matter under §101.
CONCLUSION AND CONSIDERATIONS BEYOND §101
Under modern patent law, the count (“hypothetical patent claim”)319
currently at the center of the USPTO interference proceeding would most
likely be held as patent eligible subject matter. Many people question the
ethical and moral implications of the patented CRISPR technology. 320
However, the current §101 framework does not take moral and ethical values
into consideration. Others like Tuttle are concerned that these patents will
impede rather than promote downstream research and innovation. 321
However, the hypothetical §101 invalidity dispute illustrates that under the
modern Alice framework, the CRISPR-Cas9 technology of the
Doudna/Zhang interference qualifies as patentable subject matter.
Preemption concerns can be addressed outside the scope of §101 by raising
§102 (novelty) and §103 (obviousness) issues. Hence, §101 will likely not
be an issue in future invalidity challenges. Rather, it is highly probable that
invalidity challenges as to §103 (obviousness) will be made in federal
court.322
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Further, it is important to note that the count only claims a CRISPR
system that utilizes the Cas9 nuclease. Since the introduction of the CRISPRCas9 technology in 2012, scientists have worked to find a better alternative
to Cas9.323 In 2015, Zhang discovered Cpf1, a smaller and potentially more
efficient nuclease than Cas9.324 Researchers from UCB recently discovered
CasX and CasY—two nucleases which are much smaller and potentially
more useful than Cas9.325 Further, researchers last year discovered a new
CRISPR system, C2c2, which potentially allows researchers to edit RNA
instead of DNA.326 The CRISPR-Cas9 technology allows researchers to edit
DNA and make permanent changes to a cell’s genome.327 C2c2, on the other
hand, will allow researchers to target RNA and make temporary changes to
a cell’s genome.328 Some of these researchers have filed patent applications
over their improved CRISPR systems. 329 The outcome of the current
interference proceeding will impact the scope of patent protection available
to alternative genome editing tools based on the CRISPR-Cas9
technology.330 Hence, future invalidity disputes over genome editing patents
will most likely focus on §102 (novelty) and §103 (obviousness) issues
rather than §101 issues.
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